In the spring of 2013, two businessmen from an American subsidiary of an Indian generics manufacturer travelled to Pune to visit their parent company, Emcure Pharmaceuticals. They met Satish Mehta, Emcure’s billionaire chief executive, to discuss the upcoming launch of a drug called Doxy DR.
Fix up
Inside the generics price-fixing saga in the US
Events that transpired between a few companies in the US generics market may or may not be price-fixing 101. Court documents allow, for the first time, a peek into how it allegedly went down

Read the full story.
Create a free account.
Also read our exhaustive coverage about Competition, power and monopolies, Pharma Drugs and Future of Retail
Or subscribe. Why? Let us explain.
Already Registered?
Login now